LUXEMBOURG / ACCESSWIRE / March 6, 2024 / Moolec Science SA (NASDAQ:MLEC) ("Company"; "Moolec"), a science-based food ingredient company focused on producing animal proteins in plants through Molecular Farming, announced today that it will release its Business Update for the Second Quarter Fiscal Year 2024 on Wednesday, March 13, 2024, before the market opens.
Moolec's Chief Executive Officer Gastón Paladini, Chief Financial Officer José López Lecube, and Chief Science Officer Amit Dhingra will host a live Conference Call on Wednesday, March 13, 2024, at 08:30 am ET. Henk Hoogenkamp, Chief Product Officer, will join the subsequent question-and-answer session to be held immediately after the Business Update remarks.
The Conference Call will be accompanied by a presentation, which can be viewed during the webcast. A replay and the pdf version of the presentation will be available approximately two hours after the conclusion of the live event via the company's Investor Relations website.
Connection Details:
- When: March 13, 2024 - 08:30 AM Eastern Time (US and Canada)
- Topic: Moolec Science - Business Update Conference Call Q2 FY2024
- Link to join the webinar:
https://icrinc.zoom.us/j/92375922161?pwd=Qmt6NzdVUGNWaEhTT1NDOHU3Tjlydz09 - One tap mobile: +13017158592,,92375922161#,,,,*888246# US
- Dial In: +1 301 715 8592 US | Webinar ID: 923 7592 2161 | Passcode: 888246
- International numbers available: https://icrinc.zoom.us/u/acVKYeTJwM
About Moolec Science SA
Moolec is a science-based ingredient company leader in the use of Molecular Farming technology for food. The Company's mission is to create unique food ingredients by engineering plants with animal protein genes. Its purpose is to redefine the way the world produces animal-based food, for good and for all. Moolec's technological approach aims to have the cost structure of plant-based solutions with the organoleptic properties and functionality of animal-based ones. Moolec's technology has been under development for more than a decade and is known for pioneering the production of a bovine protein in a crop for the food industry. The Company's product portfolio and pipeline leverages the agronomic efficiency of broadly used target crops, like soybean, pea, and safflower. Moolec has a growing international patent portfolio (25+, both granted and pending) for its Molecular Farming technology and a self-owned industrial and commercial R&D center (plant-based ingredient capability that includes a state-of-the-art soybean processing facility with 10,000 tons per year of installed capacity fully operational). The Company is run by a diverse team of Ph.Ds and Food Insiders, and operates in the United States, Europe, and South America.
Forward-Looking Statements
This press release contains "forward-looking statements." Forward-looking statements may be identified by the use of words such as "forecast," "intend," "seek," "target," "anticipate," "believe," "expect," "estimate," "plan," "outlook," and "project" and other similar expressions that predict or indicate future events or trends or that are not statements of historical matters. Such forward-looking statements with respect to performance, prospects, revenues, and other aspects of the business of Moolec are predictions, projections and other statements about future events that are based on current expectations and assumptions and, as a result, are subject to risks and uncertainties. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors, about which we cannot be certain. We cannot assure you that the forward-looking statements in this press release will prove accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, changes in applicable laws or regulations, the possibility that Moolec may be adversely affected by economic, business and/or other competitive factors, costs related to the scaling up of Moolec's business and other risks and uncertainties, including those included under the header "Risk Factors" in Moolec's Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission ("SEC"), as well as Moolec's other filings with the SEC. Should one or more of these risks or uncertainties materialize, or should any of our assumptions prove incorrect, actual results may vary in material respects from those projected in these forward-looking statements. We undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as may be required under applicable securities laws. Accordingly, you should not put undue reliance on these statements.
Contacts:
- Press & Media inquiries | Catalina Jones: [email protected]
- Investor Relations inquiries: [email protected] | Michael Bowen, ICR, LLC: [email protected]
Contact Information
Catalina Jones
Chief of Staff & Sustainability
[email protected]
Investor Relations
[email protected]
Michael Bowen
ICR, LLC
[email protected]
Related Files
Moolec Science Presents First Quarter Fiscal Year 2024 Business Update
SOURCE: Moolec Science
View the original press release on newswire.com.